Significant improvements in automated image analysis have been achieved over the recent years and tools are now increasingly being used in computer-assisted syndromology. However, the recognizability of the facial gestalt might depend on the syndrome and may also be confounded by severity of phenotype, size of available training sets, ethnicity, age, and sex. Therefore, benchmarking and comparing the performance of deep-learned classification processes is inherently difficult.
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Therefore, benchmarking and comparing the performance of deep-learned classification processes is inherently difficult.
For a systematic analysis of these influencing factors we chose the lysosomal storage diseases Mucolipidosis as well as Mucopolysaccharidosis type I and II, that are known for their wide and overlapping phenotypic spectra. For a dysmorphic comparison we used Smith-Lemli-Opitz syndrome as a metabolic disease and Nicolaides-Baraitser syndrome as another disorder that is also characterized by coarse facies. A classifier that was trained on these five cohorts, comprising 288 patients in total, achieved a mean accuracy of 62%.
The performance of automated image analysis is not only significantly higher than randomly expected but also better than in previous approaches. In part this might be explained by our large training sets. We therefore set up a simulation pipeline that is suited to analyze the effect of different potential confounders, such as cohort size, age, sex, or ethnic background on the recognizability of phenotypes. We found that the true positive rate increases for all analyzed disorders for growing cohorts (n= [10. ..40]) while ethnicity and sex have no significant influence.
The dynamics of the accuracies strongly suggest that the maximum recognizability is a phenotype-specific value, that hasn't been reached yet for any of the studied disorders. This should also be a motivation to further intensify data sharing efforts, as computer-assisted syndrome classification can still be improved by enlarging the available training sets.
Availability: software for classification: https://app.face2gene.com/research,
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Abbreviations: Whenever the accuracies achieved by the gestalt models in the classification of photographs are higher than randomly expected, we conclude in this study that there is a recognizable facial pattern in a cohort. The possibility of a classifier to distinguish phenotypes is referred to as recognizability and if we quantify it, the phenotype of the controls matters as well. Especially when phenotypes of the same molecular subgroup, such as lysosomal storage diseases (LSDs), are studied, recognizability also means that a clinical entity can be delineated based on the facial gestalt. While this delineation of syndromic phenotypes has been reserved to few experts in the field, computer-assisted pattern recognition now objectifies this process and makes it even quantifiable.
However, it is self-explanatory that the extent of recognizability will not only depend on the "disease-phenotype" itself, but also on additional factors in the set-up of the studied cohorts. A systematic analysis of these potential confounders is a main aspect of this work.
Patients and Methods
We analyzed the accuracy of gestalt models of the FDNA technology for a subset of disorders that have high phenotypic variability on the one hand and show a considerable phenotypic overlap on the other hand. We therefore selected Mucopolysaccharidoses (MPS I and II), which are inherited LSDs, resulting from mutations in enzymes catalyzing the breakdown of GAGs (8) . Hardly any symptoms are present at birth, but appear usually during early childhood and progress in severity during adolescence (9) . Most frequent features are abnormal bone size/shape including disproportionate short stature, contractures, intellectual disability and hearing loss (10) . A coarse facial appearance, caused by progressive GAG deposition in the soft tissue, is of particular value for the establishment of the correct diagnosis (11) . Important for our analysis was also that many cases of MPS have been published, due to its relatively high prevalence, and that the clinical diagnosis is easily confirmed by measuring enzyme activity or gene testing (12) . MPS I, which is caused by mutations in alpha-L-iduronidase (IDUA), is clinically divided according to the severity of the symptoms into three subtypes:
Hurler, Scheie, and Hurler-Scheie. MPS II, which is also referred to as Hunter syndrome, is caused by pathogenic mutations in the X-linked iduronate 2-sulfatase (I2S) and has high phenotypic similarity with MPS I. Both gene products are involved in similar processes in lysosomes where they catalyze the degradation of heparan sulfate and dermatan sulfate (11, 13) . MPS I and II are still life-threatening diseases leading to a premature death and high morbidity (14, 15) . However, for a few years enzyme replacement therapies are now available that have also been shown to attenuate the phenotypic features (16) (17) (18) (19) .
Another group of disease entities belonging to the lysosomal storage disorders are the different types of mucolipidosis (ML). In this work we focused on patients with pathogenic mutations in the alpha and beta subunits of N-acetyl-glucosamine-1-phosphotranseferase gene (GNPTAB). These subunits are part of a heterohexameric complex that catalyzes the first step of the synthesis of mannose-6-phosphat-recognition markers in the Golgi apparatus, which is a crucial step for correct trafficking of lysosomal enzymes (8) .
Hurler-like face
ML and MPS share common features, such as a coarsening of the face, organomegaly, skeletal malformations, and developmental delay, making them mutual DDx. Especially the facial gestalt of MPS and ML may be so similar that it is hard to tell the diseases apart without enzymatic or genetic testing, making them challenging choices for binary classification via computer vision.
We also added patients with Smith-Lemli-Opitz syndrome (SLOS) as another metabolic disorder and Nicolaides-Baraitser syndrome (NCBRS) as another disease phenotype that is also characterized by coarse facial features, in order to make the diagnostic workup more realistic.
From a classification point of view, we are now dealing with a five-class problem.
The original sample set of 289 clinically diagnosed patients with MPS I, II, ML, SLOS, or NCBRS is based on case reports from the literature (for references see supplemental material).
We conducted a literature search on PUBMED with the disease names and "case report" as search terms and looked for patient examples in textbooks. In addition to the patients' photos, that were the basis for the automatized image analysis, we annotated the age, when the photo 
Results

Classification of the original sample set in Face2Gene CLINIC and RESEARCH
In Face2Gene CLINIC 30 possible differential diagnoses (DDx) are listed by default per case.
If only a frontal facial photograph is uploaded and no further clinical features are annotated, these DDx represent syndromes that achieved the highest gestalt scores in the image analysis. Figure 2 shows the frequency of the five diagnoses in the study cohort among these 30 suggested diagnoses at the time of this study. MPS I and MPS II were combined in Face2Gene
CLINIC under the phenotypic series of MPS. The right diagnosis was detected in most of the cases in all cohorts. As expected from the clinical description of the diseases, MPS and ML are both listed as possible differential diagnoses in more than half of the cases. SLOS and NCBRS occur in at least 13% of the cases as DDx among the 30 top-ranked diagnoses, which is also more than randomly expected given the fact that there are several hundreds of syndromes to choose from.
Figure 2. Frequency of occurence of the five disorders as differential diagnoses in the top 30 ranks in Face2Gene CLINIC, based on gestalt scores. MPS and ML often appear both as DDx, whereas they show up less frequently in SLOS and NCBRS.
While the patient data that was used for modeling the different phenotypes in Face2Gene CLINIC, is not directly accessible, Face2Gene RESEARCH allows in silico experiments with user defined cohorts. The resulting confusion matrix for the original sample set is shown in Figure 3 as a heat map. The stronger the field is colored, the higher is the TPR or FPR. The 
Influence of growing cohort size on TPR
To analyze the influence of cohort size on the performance of the classification process, we increased the number of individuals per group stepwise from 10 to 40. TPRs with cohorts of only ten individuals were already higher than randomly expected and increased for all phenotypes with a growing cohort size, while the standard deviation decreased (Figure 4 ). The dynamics of the TPRs were fitted to a linear function and indicate that the full potential of computer-assisted classification hasn't been reached yet with the available image data.
However, we hypothesize that the number of images needed to reach the maximum In contrast to DS, we did not observe such marked differences in the MCCs for MPS I, MPS II, ML, SLOS, and NCBRS, when running the experiments for n=22 cohorts that consisted only of European patients. An analysis for another background in these disorders was not possible due to a lack of sufficient patients.
Another potential confounder in the five-class problem of MPS I, MPS II, ML, SLOS, and NCBRS that we analyzed is sex. All but two of the MPS II patients were male, whereas the sex ratios for the other disorders were close to 1. To exclude cohort size as a covariate, we sampled down to n=20 in these experiments. Interestingly, the MCC for the MPS II classification did not decrease, when also all other cohorts consisted of male patients only. This indicates that a bias in the sex ratios does not affect the performance of the classification process substantially for the tested syndromes. 
Discussion
General Recognizability
The TPRs that were achieved for all disorders in the five-class problems were higher than expected by random chance. Thus, our results show that the FDNA technology is capable of delineating gestalt differences even clinically similar phenotypes. This finding is especially remarkable for the phenotypes of MPS and ML and is also supported by high AUROC values in binary classifications (suppl. Fig. 1 ).
The difference in TPRs for the syndromes could be interpreted as different recognizabilities.
Notably, SLOS and NCBRS are more recognizable than MPS I, MPS II, and ML. This corresponds to the results from the CLINIC app, where ML shows better ranks as a differential diagnosis for MPS and vice versa. These findings are in agreement with geneticist expert opinion, who label ML as highly similar to MPS.
The high TPRs found in our analyses corresponds to the results of two other studies on phenotypes of molecular pathway disorders. For Noonan syndrome as well as for GPI-anchor deficiencies, significant phenotypic substructures could be detected. This argues in favor of a more fine-grained phenotype modelling that might also be included in the CLINIC app prospectively.
Ethnicity
MPS I could be more effectively differentiated from MPS II when cohorts were restricted to the same ethnic background. A possible explanation for this slight increase in performance might be, that there are certain features that are restricted or more prominent in European patients and that might therefore be learned more effectively if more cases are used for training the model. This issue has already been discussed for other disorders such as Fragile-X syndrome and Down syndrome were ethnic specific differences in the feature presentation are known (7, 20) . Although we could replicate these effects for DS, we did not see a prominent change in the performance in the other phenotypes, which indicates that that ethnic background is not a strong confounder in the classification process.
Sex
The human face shows a sexual dimorphism, possibly even at an early age, making sex a potential confounder in any facial image analysis process (21) . The classification accuracies in our experiments that were based on data sets adjusted to individuals of the same sex, did not significantly differ, suggesting that the classification method is robust to sex as a confounder.
Also the mean MCCs showed no significant change when training the classifier on only male individuals as compared to a training cohort consisting of both sexes. Our interpretation is that sex does not confound the classification of MPS I, MPS II, ML, SLOS, and NCBRS.
Benchmarking
We are just beginning to understand the potential of computer assisted image analysis in the field of syndromology. In this work we have presented a general approach to study the recognizability of a phenotype and to test the confounding effect of variables such as ethnicity or sex. We have applied this framework to a selection of metabolic disorders, however, it is applicable to any other disorders.
It would be most interesting to compare the performance of the FDNA technology to the accuracies of other, previously published approaches of an automated image analysis of syndromic patients. Comparative evaluation, however, is impeded by the lack of a publicly available data set for benchmarking. Earlier benchmarking approaches merely relied on the comparison to a human classification performance. To achieve an objective evaluation computer vision, we strongly advocate to build a resource for image data of molecularly confirmed syndromic cases.
